CN117653636B - 含稠合双环类化合物的抗癌药及该化合物的制药用途 - Google Patents

含稠合双环类化合物的抗癌药及该化合物的制药用途 Download PDF

Info

Publication number
CN117653636B
CN117653636B CN202311660486.7A CN202311660486A CN117653636B CN 117653636 B CN117653636 B CN 117653636B CN 202311660486 A CN202311660486 A CN 202311660486A CN 117653636 B CN117653636 B CN 117653636B
Authority
CN
China
Prior art keywords
methyl
piperazin
ethyl
dioxo
tetrahydroquinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202311660486.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN117653636A (zh
Inventor
蔡遂雄
田野
王晓珠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Therapeutics Inc
Original Assignee
Impact Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Therapeutics Inc filed Critical Impact Therapeutics Inc
Priority to CN202311660486.7A priority Critical patent/CN117653636B/zh
Publication of CN117653636A publication Critical patent/CN117653636A/zh
Application granted granted Critical
Publication of CN117653636B publication Critical patent/CN117653636B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202311660486.7A 2021-04-12 2022-04-12 含稠合双环类化合物的抗癌药及该化合物的制药用途 Active CN117653636B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311660486.7A CN117653636B (zh) 2021-04-12 2022-04-12 含稠合双环类化合物的抗癌药及该化合物的制药用途

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202110392892 2021-04-12
CN2021103928924 2021-04-12
CN2021107077396 2021-06-24
CN202110707739 2021-06-24
CN202111065912 2021-09-10
CN2021110659123 2021-09-10
CN202280011128.0A CN116783181B (zh) 2021-04-12 2022-04-12 取代的稠合双环类化合物作为parp抑制剂及其应用
CN202311660486.7A CN117653636B (zh) 2021-04-12 2022-04-12 含稠合双环类化合物的抗癌药及该化合物的制药用途
PCT/CN2022/086311 WO2022218296A1 (en) 2021-04-12 2022-04-12 Substituted fused bicyclic compounds as parp inhibitors and the use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280011128.0A Division CN116783181B (zh) 2021-04-12 2022-04-12 取代的稠合双环类化合物作为parp抑制剂及其应用

Publications (2)

Publication Number Publication Date
CN117653636A CN117653636A (zh) 2024-03-08
CN117653636B true CN117653636B (zh) 2024-04-26

Family

ID=83640149

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202311660486.7A Active CN117653636B (zh) 2021-04-12 2022-04-12 含稠合双环类化合物的抗癌药及该化合物的制药用途
CN202280011128.0A Active CN116783181B (zh) 2021-04-12 2022-04-12 取代的稠合双环类化合物作为parp抑制剂及其应用
CN202610252591.4A Pending CN121800782A (zh) 2021-04-12 2022-04-12 取代的稠合双环类化合物作为parp抑制剂及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202280011128.0A Active CN116783181B (zh) 2021-04-12 2022-04-12 取代的稠合双环类化合物作为parp抑制剂及其应用
CN202610252591.4A Pending CN121800782A (zh) 2021-04-12 2022-04-12 取代的稠合双环类化合物作为parp抑制剂及其应用

Country Status (8)

Country Link
US (1) US20240208969A1 (https=)
EP (1) EP4326713A4 (https=)
JP (1) JP2024513538A (https=)
KR (1) KR20240009929A (https=)
CN (3) CN117653636B (https=)
CA (1) CA3216489A1 (https=)
MX (1) MX2023012039A (https=)
WO (1) WO2022218296A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024050370A1 (en) * 2022-08-30 2024-03-07 1Cbio, Inc. Heterocyclic compounds and methods of use thereof
KR20250103668A (ko) * 2022-11-10 2025-07-07 치아타이 티안큉 파마수티컬 그룹 주식회사 축합 이환 화합물
TW202506680A (zh) * 2023-04-28 2025-02-16 美商思諾維新醫藥公司 作為ｐａｒｐ１抑制劑之雜環化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018781A2 (en) * 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
CN101189238A (zh) * 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001302515A (ja) * 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
JP2002284699A (ja) * 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
CN1918151A (zh) * 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
EA011552B1 (ru) * 2004-06-30 2009-04-28 Янссен Фармацевтика Н.В. Производные хиназолиндиона в качестве ингибиторов parp
JP2007137818A (ja) * 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd ８−ヒドロキシ−２，４（１ｈ，３ｈ）−キナゾリンジオン誘導体
US8404713B2 (en) * 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
ES2367760T3 (es) * 2008-03-27 2011-11-08 Janssen Pharmaceutica, N.V. Derivados de quinazolinona como inhibidores de la polimerización de la tubulina.
JP5744019B2 (ja) * 2009-07-14 2015-07-01 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 選択的ｐａｒｐ−１阻害を有する３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−カルボキサミド
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd ２−アミノ置換８−オキソジヒドロプリン誘導体
CA2829123C (en) * 2011-03-14 2016-04-12 Eternity Bioscience Inc. Quinazolinediones and their use
CN102731416A (zh) * 2011-04-01 2012-10-17 南京英派药业有限公司 1-(芳基甲基)-喹唑啉-2，4-二酮作为parp抑制剂及其应用
TWI527800B (zh) * 2011-04-01 2016-04-01 南京英派藥業有限公司 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
EP2913330A1 (en) * 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
CN109563051B (zh) * 2016-08-22 2024-06-11 南京明德新药研发有限公司 作为pde4抑制剂的并环类化合物
AU2017317123B9 (en) * 2016-08-22 2021-11-25 Medshine Discovery Inc. PDE4 inhibitor
WO2018112842A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
SI3999506T1 (sl) * 2019-07-19 2025-06-30 Astrazeneca Ab Zaviralci PARP1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018781A2 (en) * 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
CN101189238A (zh) * 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶

Also Published As

Publication number Publication date
CN116783181B (zh) 2026-01-30
CN117653636A (zh) 2024-03-08
EP4326713A4 (en) 2025-03-19
JP2024513538A (ja) 2024-03-25
WO2022218296A1 (en) 2022-10-20
EP4326713A1 (en) 2024-02-28
KR20240009929A (ko) 2024-01-23
CA3216489A1 (en) 2022-10-20
CN116783181A (zh) 2023-09-19
MX2023012039A (es) 2024-03-05
CN121800782A (zh) 2026-04-07
US20240208969A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
CN117980307A (zh) 取代的三环类化合物作为parp抑制剂及其应用
JP7240784B2 (ja) ８，９－ジヒドロイミダゾール［１，２－ａ］ピリミド［５，４－ｅ］ピリミジン－５（６Ｈ）－ケトン類化合物
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
CN117653636B (zh) 含稠合双环类化合物的抗癌药及该化合物的制药用途
CN114057771B (zh) 大环化合物及其制备方法和应用
KR102388312B1 (ko) 아미노피리미딘 화합물, 이의 제조방법 및 용도
CN119013279A (zh) 作为parp抑制剂的取代的三环类化合物及其应用
WO2017092635A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
CN118215664B (zh) 取代的三唑并杂芳基化合物作为usp1抑制剂及其应用
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN117412973A (zh) 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
CN104066723A (zh) 1-(芳基甲基)-5,6,7,8-四氢喹唑啉-2,4-二酮和相关化合物及其应用
KR20230043885A (ko) 트리시클릭 헤테로사이클
CN116670134A (zh) 取代的咪唑并[1,5-b]哒嗪化合物作为激酶抑制剂及其应用
CN114787162B (zh) 取代的咪唑并喹喔啉化合物及其应用
CN120826404A (zh) 取代的含氮三环类化合物作为parp抑制剂及其应用
HK40115331A (zh) 作为parp抑制剂的取代的三环类化合物及其应用
HK40104162A (zh) 取代的三环类化合物作为parp抑制剂及其应用
CN112480120A (zh) 取代的咪唑并喹喔啉化合物及其应用
BR112019025836B1 (pt) Composto de aminopirimidina, seu método de preparação, composição farmacêutica e seu uso

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant